BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 13, 2012
 |  BioCentury  |  Product Development

Amped up antiviral

First POC data for Chimerix's CMX001 cidofovir for CMV in transplant patients

Antivirals approved for use in transplant patients are not active against all double-stranded DNA viruses and carry black-box warnings for nephrotoxicity and myelosuppression. Based on Phase II data, Chimerix Inc.'s broad-spectrum CMX001 may offer a way to treat and prevent CMV infection in hematopoietic stem cell transplant patients without the severe side effects seen with other antivirals.

Cytomegalovirus (CMV) is a member of the herpes virus family that is present in about half of U.S. adults. It is typically asymptomatic but its effects can be severe in immunocompromised individuals. In transplant patients, for example, CMV reactivation can lead to transplant failure, other organ failure and death.

In addition to CMV, many transplant recipients are at risk of severe infection from reactivation or transmission of other viruses, including adenovirus, Epstein-Barr virus (EBV), BK virus (BKV) and polyomavirus JC (JCV).

However, antivirals approved for the transplant setting, such as the generic ganciclovir and Valcyte valganciclovir from Roche and Mitsubishi Tanabe Pharma Corp., target only viruses in the herpes family such as CMV, HSV and EBV.

CMX001 is an oral lipid-antiviral-conjugate that delivers active cidofovir, a double-stranded DNA viral synthesis inhibitor. While Vistide cidofovir from Gilead Sciences Inc. is approved to treat CMV infection in the retina of AIDS patients, cidofovir has activity against the broad range of viruses that pose...

Read the full 1101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >